ES2170856T3 - Vectores retroviricos. - Google Patents

Vectores retroviricos.

Info

Publication number
ES2170856T3
ES2170856T3 ES96914342T ES96914342T ES2170856T3 ES 2170856 T3 ES2170856 T3 ES 2170856T3 ES 96914342 T ES96914342 T ES 96914342T ES 96914342 T ES96914342 T ES 96914342T ES 2170856 T3 ES2170856 T3 ES 2170856T3
Authority
ES
Spain
Prior art keywords
gene
dna provirus
ltr
regulatory factor
vectors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96914342T
Other languages
English (en)
Inventor
Alan John Kingsman
Susan Mary Kingsman
Paula Marie Cannon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Biomedica UK Ltd
Original Assignee
Oxford Biomedica UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Biomedica UK Ltd filed Critical Oxford Biomedica UK Ltd
Application granted granted Critical
Publication of ES2170856T3 publication Critical patent/ES2170856T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE DESCRIBEN VECTORES RETROVIRICOS QUE RESULTAN UTILES PARA LA TERAPIA GENICA. EL GENOMA DE ARN QUE PUEDE ENCAPSULARSE DEL VECTOR SUMINISTRA EN EL PROVIRUS DE ADN UN PROMOTOR REGULADO, QUE RESULTA INDUCIBLE POR UN FACTOR REGULADOR, POR EJEMPLO, LA PROTEINA TRANSACTIVADORA TAT DEL VIH, Y AL MENOS UN GEN SELECCIONADO BAJO SU CONTROL TRANSCRIPCIONAL. EN EL PROVIRUS DE ADN, EL PROMOTOR REGULADO SE ENCUENTRA PRESENTE EN LA REPETICION TERMINAL LARGA 5 (LTR) EN LUGAR DE LA FUNCION PROMOTORA LTR5 DEL RETROVIRUS, Y EL GEN SELECCIONADO SE ENCUENTRA ENTRE LAS LTR. POR TANTO, CUANDO SE INSERTA EN UNA CELULA HUESPED, EL GEN SOLO SERA EXPRESADO CUANDO EL PROVIRUS DE ADN SEA EXPUESTO AL FACTOR REGULADOR.
ES96914342T 1995-05-22 1996-05-22 Vectores retroviricos. Expired - Lifetime ES2170856T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9510272.9A GB9510272D0 (en) 1995-05-22 1995-05-22 Retroviral vectors

Publications (1)

Publication Number Publication Date
ES2170856T3 true ES2170856T3 (es) 2002-08-16

Family

ID=10774804

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96914342T Expired - Lifetime ES2170856T3 (es) 1995-05-22 1996-05-22 Vectores retroviricos.

Country Status (10)

Country Link
US (1) US6096538A (es)
EP (2) EP1164196B1 (es)
JP (1) JP3886531B2 (es)
AT (2) ATE213780T1 (es)
DE (2) DE69619514T2 (es)
DK (1) DK0827545T3 (es)
ES (1) ES2170856T3 (es)
GB (1) GB9510272D0 (es)
PT (1) PT827545E (es)
WO (1) WO1996037623A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4037446B2 (ja) 1994-09-02 2008-01-23 ゲーエスエフ − フォルシュンクスツェントルム・フューア・ウムベルト・ウント・ゲズントハイト・ゲーエムベーハー 非自己不活化性の発現標的化レトロウイルスベクタ
WO1996028563A1 (en) 1995-03-09 1996-09-19 Bavarian Nordic Vectors carrying therapeutic genes encoding antimicrobial peptides for gene therapy
AU721326B2 (en) * 1996-02-13 2000-06-29 Fred Hutchinson Cancer Research Center 10A1 retroviral packaging cells and uses thereof
US6776986B1 (en) 1996-06-06 2004-08-17 Novartis Ag Inhibition of HIV-1 replication by antisense RNA expression
GB9621680D0 (en) * 1996-10-17 1996-12-11 Oxford Biomedica Ltd Lentiviral vectors
US6924123B2 (en) 1996-10-29 2005-08-02 Oxford Biomedica (Uk) Limited Lentiviral LTR-deleted vector
GB9622500D0 (en) 1996-10-29 1997-01-08 Oxford Biomedica Ltd Therapeutic gene
GB9703802D0 (en) * 1997-02-24 1997-04-16 Kingsman Susan M Anti-hiv peptides and proteins
GB9711578D0 (en) * 1997-06-04 1997-07-30 Oxford Biomedica Ltd Novel retroviral vector production systems
CA2304983A1 (en) 1997-09-24 1999-04-01 The Regents Of The University Of California Non-primate lentiviral vectors and packaging systems
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6790657B1 (en) 1999-01-07 2004-09-14 The United States Of America As Represented By The Department Of Health And Human Services Lentivirus vector system
JP4824236B2 (ja) * 1999-07-09 2011-11-30 ジェン−プローブ・インコーポレーテッド 核酸増幅によるｈｉｖ−１の検出
AP1674A (en) 1999-11-16 2006-10-30 Geneart Ag The genome of the HIV-1 inter-subtype (C/B') and use thereof.
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
US20030039636A1 (en) * 2001-05-01 2003-02-27 Genetix Pharmaceuticals, Inc. Novel self-inactivating (SIN) lentiviral vectors
ATE527347T1 (de) 2001-08-02 2011-10-15 Inst Clayton De La Rech Verfahren und zusammensetzungen im zusammenhang mit verbesserten lentivirusvektor- produktionssystemen
US7737124B2 (en) 2001-09-13 2010-06-15 California Institute Of Technology Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell
JP4344858B2 (ja) * 2001-09-13 2009-10-14 カリフォルニア インスティチュート オブ テクノロジー 細胞内で抗ウイルス性小ｒｎａ分子を発現させる方法
US7195916B2 (en) * 2001-09-13 2007-03-27 California Institute Of Technology Method for expression of small antiviral RNA molecules within a cell
RU2305708C2 (ru) * 2001-10-02 2007-09-10 Энститю Клейтон Де Ля Решерш Рекомбинантный лентивирусный вектор, клетка-хозяин, трансдуцированная лентивирусным вектором, способ ее трансдукции и применение
SI1504108T1 (sl) 2002-02-01 2013-07-31 Oxford Biomedica (Uk) Limited Lentiviralni vektor
US9738907B2 (en) 2002-02-01 2017-08-22 Oxford Biomedica (Uk) Limited Viral vector
US7135324B2 (en) 2002-09-04 2006-11-14 The University Of Connecticut Viral recombinases, related articles, and methods of use thereof
US20050014166A1 (en) * 2002-11-22 2005-01-20 Institut Clayton De La Recherche Compositions and systems for the regulation of genes
US7297536B2 (en) * 2003-01-23 2007-11-20 Wisconsin Alumni Research Foundation Inducible protein expression system
ES2221578B1 (es) * 2003-06-13 2006-03-01 Universidad De Jaen Vector diseñado para la destruccion de los virus latentes en el tratamiento de la infeccion por el virus de la inmunodeficiencia humana tipo 1 (vih-1) mediante terapia genica.
GB201318804D0 (en) 2013-10-24 2013-12-11 Adaptimmune Ltd Vectors for transgene expression
GB201322798D0 (en) 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
WO2019245817A1 (en) 2018-06-19 2019-12-26 Armo Biosciences, Inc. Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy
WO2021094752A1 (en) 2019-11-12 2021-05-20 Oxford Biomedica (Uk) Limited Production system

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4738922A (en) * 1984-05-25 1988-04-19 Dana Farber Cancer Institute Trans-acting transcriptional factors
US5591624A (en) * 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
US5665577A (en) * 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US5672510A (en) * 1990-01-19 1997-09-30 Genetic Therapy, Inc. Retroviral vectors
CA2557882C (en) * 1992-02-28 2010-05-18 Syngenix Limited Defective packaging non-oncoviral vectors based on mpmv and hiv
GB9305759D0 (en) * 1993-03-19 1993-05-05 Medical Research Council And T Hiv therapy method and agents
WO1994029437A1 (en) * 1993-06-07 1994-12-22 University Of Medicine & Dentistry Of New Jersey Highly-efficient, self-inactivating, recombination-free, u3-free retroviral vectors
WO1995030755A1 (en) * 1994-05-10 1995-11-16 Hisamitsu Pharmaceutical Co., Inc. Recombinant human immunodeficiency virus vector and process for producing the same
US5693508A (en) * 1994-11-08 1997-12-02 Chang; Lung-Ji Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats

Also Published As

Publication number Publication date
EP0827545B1 (en) 2002-02-27
US6096538A (en) 2000-08-01
JPH11511005A (ja) 1999-09-28
DE69619514T2 (de) 2002-07-11
ATE213780T1 (de) 2002-03-15
WO1996037623A1 (en) 1996-11-28
EP1164196B1 (en) 2006-09-27
JP3886531B2 (ja) 2007-02-28
ATE340864T1 (de) 2006-10-15
GB9510272D0 (en) 1995-07-19
PT827545E (pt) 2002-07-31
DK0827545T3 (da) 2002-06-10
DE69636581T2 (de) 2007-05-31
EP0827545A2 (en) 1998-03-11
DE69636581D1 (de) 2006-11-09
EP1164196A1 (en) 2001-12-19
DE69619514D1 (de) 2002-04-04

Similar Documents

Publication Publication Date Title
ES2170856T3 (es) Vectores retroviricos.
ATE520783T1 (de) Lentivirale vektoren
WO1996037623B1 (en) Retroviral vectors
DK1895010T3 (da) Vektorer baseret på virus for infektiøs hesteanæmi (eiav)
DE3585072D1 (de) Retroviraler vektor.
FI940867A0 (fi) Ilmentämisrakenteita, jotka sisältävät HIV:iä estäviä antisense- ja muita nukleotidisekvenssejä, retrovirusvektoreita ja näitä sisältäviä yhdistelmäretroviruksia
Graveley et al. A common mechanism for the enhancement of mRNA 3'processing by U3 sequences in two distantly related lentiviruses
DK0801575T3 (da) Retrovirale vektorer til ekspression i embryoniske celler
WO1994020621A3 (en) Proteinaceous particles containing retroviral element
Proudfoot et al. Multiple SP1 binding sites confer enhancer-independent, replication-activated transcription of HIV-1 and globin gene promoters
DE69121118D1 (de) Genexpression in Hefezellen
ATE406452T1 (de) Retrovirale vektoren
DK631387A (da) Virusvektor
Fukumori et al. Rev-dependent expression of three species of HIV-1 mRNAs
Ju et al. Nucleotide sequence analysis of avian retroviruses: structural similarities with transposable elements
SHUMAN THE AVIAN RETROVIRUS AS A POTENTIAL VECTOR FOR GENE TRANSFER IN THE CHICKEN (LEUKOSIS VIRUS, RETICULOENDOTHELIOSIS)
RU99109988A (ru) Лентивирусные векторы

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 827545

Country of ref document: ES